Scholar Rock to be Acquired by Ares Management for $1 Billion

Ticker: SRRK · Form: 8-K · Filed: Oct 14, 2025 · CIK: 1727196

Sentiment: bullish

Topics: acquisition, merger, private-equity

TL;DR

Ares buying Scholar Rock for $1B cash ($20/share), deal expected Q1 2026.

AI Summary

Scholar Rock Holding Corp. announced on October 10, 2025, that it has entered into a definitive agreement to be acquired by an affiliate of Ares Management LLC. The transaction is valued at approximately $1.0 billion, with shareholders expected to receive $20.00 per share in cash. The acquisition is anticipated to close in the first quarter of 2026, subject to customary closing conditions.

Why It Matters

This acquisition by a major investment firm like Ares Management suggests a significant valuation of Scholar Rock's pipeline and potential, potentially impacting the biotech investment landscape.

Risk Assessment

Risk Level: medium — The deal is subject to customary closing conditions and regulatory approvals, which could lead to delays or the deal not closing.

Key Numbers

Key Players & Entities

FAQ

Who is acquiring Scholar Rock Holding Corp.?

An affiliate of Ares Management LLC is acquiring Scholar Rock Holding Corp.

What is the total value of the acquisition?

The definitive agreement values the transaction at approximately $1.0 billion.

How much will shareholders receive per share?

Shareholders are expected to receive $20.00 per share in cash.

When is the acquisition expected to close?

The transaction is anticipated to close in the first quarter of 2026.

What is the filing date of this report?

This Form 8-K was filed on October 14, 2025, reporting an event on October 10, 2025.

Filing Stats: 404 words · 2 min read · ~1 pages · Grade level 12 · Accepted 2025-10-14 06:08:39

Key Financial Figures

Filing Documents

01. Other Events

Item 8.01. Other Events. On October 10, 2025, Novo Nordisk informed Scholar Rock Holding Corporation (the "Company") that, following the Form FDA 483 issued to Catalent Indiana, LLC (owned by Novo Nordisk) on July 14, 2025, the U.S. Food and Drug Administration has determined that the inspection classification of this facility is "official action indicated". SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Scholar Rock Holding Corporation Date: October 14, 2025 By: /s/ Junlin Ho Junlin Ho General Counsel & Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing